Immune checkpoint inhibitor targets

Immune checkpoint inhibitor targets are cell-surface proteins, most notably **PD-1**, **CTLA-4**, **PD-L1**, and newer proteins such as **LAG-3**, that function as negative regulators of the immune response. These checkpoints are essential for maintaining self-tolerance and modulating the strength and duration of immune responses, thereby preventing autoimmunity. Tumor cells can exploit these pathways by expressing ligands like PD-L1, thereby inhibiting T cell–mediated antitumor responses. Immune checkpoint inhibitors are monoclonal antibodies that block these inhibitory signals, thereby restoring and enhancing T cell activity against cancer cells. Their use has revolutionized the management of various cancers but is associated with distinctive immune-related toxicities requiring careful management[1][2][4][5][6]. **Note:** "Immune checkpoint inhibitor targets" is not a canonical molecular target name, but instead refers to a group or family of proteins. For structured data, each target (e.g., PD-1, CTLA-4, PD-L1, LAG-3) should be extracted and described separately for precise records.

Other names

Immune checkpoint moleculesimmune inhibitory receptorscoinhibitory immune receptorscheckpoint proteinsimmune inhibitory ligands

Monoclonal antibody blockade of immune checkpoint receptors (e.g., PD-1, CTLA-4, LAG-3), preventing their interaction with ligands and thus relieving inhibitory signals on T cells, allowing enhanced immune-mediated destruction of tumor cells[4][5][6].